Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 10, Issue 4, 2016, Pages 395-401

  Marthey, L ^a,b   Mateus, C ^c   Mussini, C ^a   Nachury, M ^d   Nancey, S ^e   Grange, F ^f   Zallot, C ^g   Peyrin Biroulet, L ^g   Rahier, J F ^h   de Beauregard, M Bourdier ⁱ   Mortier, L ^d   Coutzac, C ^c   Soularue, E ^a   Lanoy, E ^c,j   Kapel, N ^k   Planchard, D ^c   Chaput, N ^c,j,l   Robert, C ^c   Carbonnel, Franck ^a  

^a BICÊTRE HOSPITAL   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f SERVICE DE DERMATOLOGIE   (France)

^g UNIVERSITÉ DE LORRAINE   (France)

^h UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

ⁱ UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^j INSERM   (France)

^k ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^l CNRS   (France)

more..

Author keywords

Anti CTLA 4; Enterocolitis; Ipilimumab

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALGRANULIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GEFITINIB; INFLIXIMAB; IPILIMUMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; STEROID; TICILIMUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ABDOMINAL ABSCESS; ADULT; AGED; ANEMIA; ANUS FISSURE; ANUS FISTULA; ARTHRALGIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER THERAPY; CLINICAL ARTICLE; COLITIS; COLON BIOPSY; COLON OBSTRUCTION; COLON PERFORATION; COLON RESECTION; COLON ULCER; COLONOSCOPY; DIARRHEA; DRUG WITHDRAWAL; DUODENITIS; ENDOSCOPIC BIOPSY; ENTEROCOLITIS; ESOPHAGUS ULCER; FEMALE; FOLLOW UP; GASTRITIS; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSITIS; ILEAL INFLAMMATION; ILEOSTOMY; ILEUM DISEASE; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; MALE; MELANOMA; METASTATIC MELANOMA; MOUTH ULCER; NEPHRITIS; NON SMALL CELL LUNG CANCER; PANCREATITIS; PERIANAL ABSCESS; PERICARDITIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; RECTUM ULCER; REMISSION; SIDE EFFECT; SIGMOID ULCER; THYROIDITIS; TOXIC MEGACOLON; TREATMENT RESPONSE; ADVERSE EFFECTS; CHEMICALLY INDUCED; COLON; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; PATHOLOGY; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COLECTOMY; COLON; CTLA-4 ANTIGEN; ENTEROCOLITIS; FEMALE; HUMANS; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASES; MALE; MELANOMA; MIDDLE AGED; YOUNG ADULT;

EID: 84966267366     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv227     Document Type: Article

References (35)

1. Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909-11.
2. Azuma M, Ito D, Yagita H, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993;366:76-9.
3. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-65.
4. McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol 1999;77:1-10
5. Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev 2006;212:131-48.
6. Bulliard Y, Jolicoeur R, Windman M, et al. Activating Fc ? receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013;210:1685-93.
7. Wang CJ, Kenefeck R, Wardzinski L, et al. Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells. J Immunol 2012;189:1118-22.
8. Romano E, Kusio-Kobialka M, Foukas PG, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA 2015;112:6140-5.
9. Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013;1:32-42.
10. Hodi FS, O'Day SJ, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
11. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517- 26.
12. Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatmentnaive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015;33:1191-6.
13. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV nonsmall- cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046-54.
14. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte- associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100:4712-7.
15. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008;105:3005-10.
16. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825-30.
17. Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009;69:609-15.
18. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:700-12.
19. Tarhini AA, Cherian J, Moschos SJ, et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 2012;30:322-8.
20. Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010;16:1042-8.
21. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013;31:616-22.
22. Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013;14:1104-11.
23. McNeel DG, Smith HA, Eickhoff JC, et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSArecurrent prostate cancer. Cancer Immunol Immunother 2012;61:1137-47.
24. Aglietta M, Barone C, Sawyer MB, et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy- naive patients with metastatic pancreatic cancer. Ann Oncol 2014;25:1750-5.
25. Sangro B, Gomez-Martin C, De la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
26. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010;37:499-507.
27. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-7.
28. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen J Clin Oncol 2006 24:2283-9.
29. Gupta A, De Felice KM, Loftus EV, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015;42:406-17.
30. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-4
31. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010;10:11.
32. Ananthakrishnan AN, Higuchi LM, Huang ES, et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med 2012;156:350-9.
33. Zeissig S, Petersen BS, Tomczak M, et al. Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4. Gut 2014;0:1-9.
34. Kuehn HS, Ouyang W, Lo B, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 2014;345:1623-7.
35. Barnes MJ, Griseri T, Johnson AM, et al. CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria. Mucosal Immunol 2013;6:324-34.